Table 5.
Results of sputum samples from new suspected MDR-PTB cases tested using Xpert MTB/RIF and MGIT 960 System during 2016–2018.
| Total sputum samples | Xpert MTB/RIF | MGIT 960 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 59 | MTBC Pos (55/59, 93.22%) | MTBC Pos (55/59, 93.22%) | |||||||
| RS | RR | RS | HS | SS | ES | AmkS | KmS | OflS | |
| 0/55 (0%) | 55/55 (100%) | 13/55 (23.63%) | 25/55 (45.45%) | 48/55 (87.27%) | 42/55 (76.36%) | 55/55 (100%) | 52/55 (94.54%) | 49/55 (89.09%) | |
RS: Rifampicin sensitive; RR: Rifampicin resistant; HS: Isoniazid sensitive; SS: Streptomycin sensitive; ES: Ethambutol sensitive; AmkS: Amikacin sensitive; KmS: Kanamycin sensitive OflS: Ofloxacin sensitive.